Related Experiment Video

Updated: Jun 27, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.6K

Kick-Starting Molecular Theranostics in Renal Cell Carcinoma

Viktor Grünwald1,2, Boris Hadschik3, Niklas Klümper4,5

  • 1Department for Urology, University Hospital Essen, Essen, Germany; viktor.gruenwald@uk-essen.de.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|May 1, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Related Experiment Videos

Last Updated: Jun 27, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.6K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

Articles linked to this work by shared authors, journal, and citation graph.

Radioligand therapies in cancer: mapping the educational landscape in Europe.

European journal of nuclear medicine and molecular imaging·2023

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.

International journal of molecular sciences·2023

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023

Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times.

European radiology·2023

Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023

Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.

Journal of neurology·2023

PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Safety, Biodistribution, and Dosimetry of FAP and Integrin αvβ3 Dual-Targeting Radioligand 177Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

The Global Theranostics Access Gap: Real-World Disparities in PSMA PET/CT and 177Lu-PSMA Therapy Between Centers in Brazil and Europe.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

68Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

2026 SNMMI Highlights Lecture: Cardiovascular Sciences.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us